Document Type : Original Article
Authors
- . Seyed Ghafur Mousavi 1
- . Hamze Rostami 1
- . Mohammad Reza Sharbafchi 2
- . Atefeh Saeidi Boroujeni 3
- . Behzad Mahaki 4
1 Department of Psychiatry, Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Psychiatry, Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Psychiatry, Azad University of Najaf Abad, Isfahan, Iran
4 Department of Biostatistics, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Objective: Antipsychotic medications are the frontline treatment for the most psychotic
disorders. The aim of this study is to compare the onset of action of the first and second
generation antipsychotics and the rate of their side‑effects in the treatment of acute
psychosis.
Methods: In a double‑blind, controlled clinical trial, 40 acute psychotic patients were
randomly allocated in four groups and treated with each of the four antipsychotics:
olanzapine, risperidone, haloperidol or thiothixene. The onset of action of each drug
was assessed by the Positive and Negative Symptoms Scale. The data were analyzed by
Wilcoxon (Gehan) survival and Log Rank analysis, using SPSS version 20.0.
Findings: Initial response was observed in 97.5% (N = 39) of subjects during 2 weeks of
intervention. The mean time to the first response was 6.15 ± 2.9 days and this was significantly
shorter for risperidone than others. The most common side‑effects were sedation and
drug induced Parkinsonism.
Conclusion: Risperidone represented shorter onset of action for the treatment of acute
psychotic symptoms compared with olanzapine, haloperidol and thiothixene.
Keywords
- Lewis S, Escalona PR, Keith SJ. Phenomenology of
Schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P, editors.
Kaplan and Sadock’s Comprehensive Textbook of Psychiatry.
9th ed. New York: Lippincott Williams and Wilkins; 2009.
p. 1433-51.
2. Lieberman JA, Fenton WS. Delayed detection of psychosis:
Causes, consequences, and effect on public health. Am J
Psychiatry 2000;157:1727-30.
3. Fenton WS, Blyler CR, Heinssen RK. Determinants of
medication compliance in schizophrenia: Empirical and
clinical findings. Schizophr Bull 1997;23:637‑51.
4. Malla A, Norman R, Schmitz N, Manchanda R, BéchardEvans L, TakharJ, et al. Predictors of rate and time to remission
in first‑episode psychosis: A two‑year outcome study. Psychol
Med 2006;36:649-58.
5. Lieberman JA, Tollefson GD, Charles C, ZipurskyR, Sharma T,
KahnRS, et al. Antipsychotic drug effects on brain morphology
in first‑episode psychosis. Arch Gen Psychiatry 2005;62:361‑70.
6. Tohen M, Strakowski SM, Zarate C Jr, Hennen J, Stoll AL,
Suppes T, et al. The McLean‑Harvard first‑episode project:
6‑month symptomatic and functional outcome in affective
and nonaffective psychosis. Biol Psychiatry 2000;48:467‑76.
7. Robinson DG, Woerner MG, McMeniman M, MendelowitzA,
Bilder RM. Symptomatic and functional recovery from a first
episode of schizophrenia or schizoaffective disorder. Am J
Psychiatry 2004;161:473-9.
8. BilderRM, GoldmanRS, Robinson D, Reiter G, Bell L, Bates JA,
et al. Neuropsychology of first‑episode schizophrenia: Initial
characterization and clinical correlates. Am J Psychiatry
2000;157:549-59.
9. Miyamoto S, Lieberman JA, Fleischhacker WW, Aoba A,
Marder SR. Antipsychotic drugs. In: Tasman A, Kay J,
Lieberman JA, editors. Psychiatry. 2nd edition. Chichester:
John Wiley and Sons, Ltd.; 2003. p. 1928-64.
10. Buckley PF. Broad therapeutic uses of atypical antipsychotic
medications. Biol Psychiatry 2001;50:912-24.
11. Kane JM, Leucht S, Carpenter D, Docherty JP, Expert
Consensus Panel for Optimizing Pharmacologic Treatment of
Psychotic Disorders. The expert consensus guideline series.
Optimizing pharmacologic treatment of psychotic disorders.
Introduction: Methods, commentary, and summary. J Clin
Psychiatry 2003;64 Suppl 12:5-19.
12. McEvoy JP, Scheifler PL, Frances A. The expert consensus
guideline series: Treatment of schizophrenia. J Clin Psychiatry
1999;60:1-80.
13. Miyamoto S, Stroup TS, Duncan GE, Aoba A, Lieberman JA.
Acute pharmacologic treatment of schizophrenia. In:
Hirsch SR, Weinberger DR, editors. Schizophrenia. 2nd ed.
Oxford: Blackwell Science; 2003. p. 442-73.
14. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD,
Kopala L, et al. Risperidone and haloperidol in first‑episode
psychosis: A long-term randomized trial. Am J Psychiatry
2005;162:947-53.
15. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE,
Kahn R, et al. Comparative efficacy and safety of atypical and
conventional antipsychotic drugs in first‑episode psychosis:
A randomized, double-blind trial of olanzapine versus
haloperidol. Am J Psychiatry 2003;160:1396-404.
16. Emsley RA. Risperidone in the treatment of first‑episode
psychotic patients: A double-blind multicenter study.
Risperidone Working Group. Schizophr Bull 1999;25:721-9.
17. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr,
Tollefson GD. Olanzapine versus haloperidol treatment in
first‑episode psychosis. Am J Psychiatry 1999;156:79‑87. - 18. Crespo‑Facorro B, Pérez‑Iglesias R, Ramirez‑Bonilla M,
Martínez-García O, Llorca J, Luis Vázquez-Barquero J.
A practical clinical trial comparing haloperidol, risperidone,
and olanzapine for the acute treatment of first-episode
nonaffective psychosis. J Clin Psychiatry 2006;67:1511‑21.
19. Remington G. Understanding antipsychotic “atypicality”:
A clinical and pharmacological moving target. J Psychiatry
Neurosci 2003;28:275-84.
20. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS,
RosenheckRA, Perkins DO, et al. Effectiveness of antipsychotic
drugs in patients with chronic schizophrenia. N Engl J Med
2005;353:1209-23.
21. Kahn RS, Fleischhacker WW, Boter H, Davidson M,
Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs
in first‑episode schizophrenia and schizophreniform disorder:
An open randomised clinical trial. Lancet 2008;371:1085-97.
22. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H,
Lazarus A, et al. Efficacy and tolerability of olanzapine,
quetiapine, and risperidone in the treatment of early
psychosis: A randomized, double-blind 52-week comparison.
Am J Psychiatry 2007;164:1050-60.
23. Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for
first‑episode schizophrenia: Acomparative review. CNS Drugs
2009;23:837-55.
24. Agid O, Seeman P, Kapur S. The “delayed onset” of
antipsychotic action –An idea whose time has come and gone.
J Psychiatry Neurosci 2006;31:93-100.
25. Kane JM, Stroup TS, Marder SR. Schizophrenia:
Pharmacological treatment. In: Sadock BJ, Sadock VA, Ruiz P,
editors. Kaplan and Sadock’s Comprehensive Textbook of
Psychiatry. 9th ed. New York: Lippincott Williams and Wilkins;
2009. p. 1547-56.28.
26. Nordström AL, Farde L, Halldin C. Time course of
D2-dopamine receptor occupancy examined by PET after
single oral doses of haloperidol. Psychopharmacology (Berl)
1992;106:433-8.
27. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S.
Significant dissociation of brain and plasma kinetics with
antipsychotics. Mol Psychiatry 2002;7:317-21.
28. Lambert M, Conus P, Schimmelmann BG, Eide P, Ward J,
Yuen H, et al. Comparison of olanzapine and risperidone
in 367 first‑episode patients with non‑affective or affective
psychosis: Results of an open retrospective medical record
study. Pharmacopsychiatry 2005;38:206-13.
29. Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ.
Efficacy and tolerability of ziprasidone versus risperidone
in patients with acute exacerbation of schizophrenia or
schizoaffective disorder: An 8‑week, double‑blind, multicenter
trial. J Clin Psychiatry 2004;65:1624-33.
30. Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S,
Jones B. Evidence for onset of antipsychotic effects within the
first 24 hours of treatment. Am J Psychiatry 2005;162:939‑46.
31. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone
compared with intramuscular haloperidol in the treatment
of acute psychosis. Ziprasidone I.M. Study Group. J Clin
Psychiatry 2000;61:933-41.
32. Zedkova I, Dudova I, Urbanek T, Hrdlicka M. Onset of action
of atypical and typical antipsychotics in the treatment of
adolescent schizophrenic psychoses. Neuro Endocrinol Lett
2011;32:667-70.
33. Kay SR, Fiszbein A, Opler LA. The positive and negative
syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987;13:261-76.
34. van Kammen DP, Hurford I, Marder SR. First-generation
antipsychotics. In: Sadock BJ, Sadock VA, Ruiz P, editors.
Kaplan and Sadock’s Comprehensive Textbook of Psychiatry.
9th ed. New York: Lippincott Williams and Wilkins; 2009.
p. 3105-27.
35. Kay SR, Opler LA, LindenmayerJP. Reliability and validity of
the positive and negative syndrome scale for schizophrenics.
Psychiatry Res 1988;23:99-110.
36. World Health Organization. Process of translation and
adaptation of instruments. Available from: http://www.who.
int/substance_abuse/research_tools/translation/en/. [Last
accessed on 2013 Dec 11].
37. Munetz MR, Benjamin S. How to examine patients using the
abnormal involuntary movement scale. Hosp Community
Psychiatry 1988;39:1172-7.
38. Lim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH. Comparison
of risperidone orodispersible tablet and intramuscular
haloperidol in the treatment of acute psychotic agitation:
A randomized open, prospective study. Neuropsychobiology
2010;62:81-6.
39. SikichL, HamerRM, BashfordRA, SheitmanBB, LiebermanJA.
A pilot study of risperidone, olanzapine, and haloperidol in
psychotic youth: A double-blind, randomized, 8-week trial.
Neuropsychopharmacology 2004;29:133-45.
40. Möller HJ, Riedel M, Jäger M, Wickelmaier F, Maier W,
Kühn KU, et al. Short-term treatment with risperidone or
haloperidol in first‑episode schizophrenia: 8‑week results of
a randomized controlled trial within the German Research
Network on Schizophrenia. Int J Neuropsychopharmacol
2008;11:985-97
)